Alcon Stock Rated Buy by BTIG Following TRYPTYR Approval
On May 30, BTIG analysts reaffirmed their Buy rating and $99 price target for Alcon Inc. (NYSE:ALC) following the FDA's approval of TRYPTYR for the treatment of dry eye disease (DED).
No. | Hedge Fund | Shares | Value | Activity | % Port |
---|---|---|---|---|---|
1. | GAMCO Investors Mario Gabelli | 0 | $0 | 0% | |
2. | Kingstown Capital Management Michael Blitzer | 0 | $0 | 0% | |
3. | Royce & Associates Chuck Royce | 0 | $0 | 0% | |
4. | AQR Capital Management Cliff Asness | 0 | $0 | 0% | |
5. | Touradji Capital Management Paul Touradji | 0 | $0 | 0% |